nodes	percent_of_prediction	percent_of_DWPC	metapath
Bromocriptine—ABCB1—ovarian cancer	0.378	1	CbGaD
Bromocriptine—ABCB1—Topotecan—ovarian cancer	0.0363	0.221	CbGbCtD
Bromocriptine—ABCB1—Vinorelbine—ovarian cancer	0.0256	0.156	CbGbCtD
Bromocriptine—CYP3A4—Topotecan—ovarian cancer	0.0218	0.133	CbGbCtD
Bromocriptine—ABCB1—Paclitaxel—ovarian cancer	0.018	0.11	CbGbCtD
Bromocriptine—CYP3A4—Vinorelbine—ovarian cancer	0.0153	0.0935	CbGbCtD
Bromocriptine—ABCB1—Docetaxel—ovarian cancer	0.013	0.0792	CbGbCtD
Bromocriptine—CYP3A4—Paclitaxel—ovarian cancer	0.0108	0.0657	CbGbCtD
Bromocriptine—ABCB1—Doxorubicin—ovarian cancer	0.00969	0.0591	CbGbCtD
Bromocriptine—HTR7—vein—ovarian cancer	0.00854	0.115	CbGeAlD
Bromocriptine—CYP3A4—Docetaxel—ovarian cancer	0.00779	0.0475	CbGbCtD
Bromocriptine—CYP3A4—Doxorubicin—ovarian cancer	0.0058	0.0354	CbGbCtD
Bromocriptine—HTR2A—vein—ovarian cancer	0.00533	0.0717	CbGeAlD
Bromocriptine—DRD4—testis—ovarian cancer	0.00251	0.0338	CbGeAlD
Bromocriptine—ADRA1D—epithelium—ovarian cancer	0.00222	0.0298	CbGeAlD
Bromocriptine—DRD5—female reproductive system—ovarian cancer	0.00205	0.0276	CbGeAlD
Bromocriptine—HTR2B—myometrium—ovarian cancer	0.00196	0.0264	CbGeAlD
Bromocriptine—DRD5—female gonad—ovarian cancer	0.00187	0.0251	CbGeAlD
Bromocriptine—ADRA1D—female reproductive system—ovarian cancer	0.00165	0.0221	CbGeAlD
Bromocriptine—ADRA2C—myometrium—ovarian cancer	0.00155	0.0208	CbGeAlD
Bromocriptine—HTR2B—uterine cervix—ovarian cancer	0.00153	0.0206	CbGeAlD
Bromocriptine—HTR2B—decidua—ovarian cancer	0.00146	0.0196	CbGeAlD
Bromocriptine—HTR2B—endometrium—ovarian cancer	0.00138	0.0186	CbGeAlD
Bromocriptine—HTR7—epithelium—ovarian cancer	0.00132	0.0178	CbGeAlD
Bromocriptine—HTR2B—uterus—ovarian cancer	0.00127	0.0171	CbGeAlD
Bromocriptine—ADRA1A—epithelium—ovarian cancer	0.00127	0.0171	CbGeAlD
Bromocriptine—HTR1B—female reproductive system—ovarian cancer	0.00127	0.0171	CbGeAlD
Bromocriptine—ADRA2A—myometrium—ovarian cancer	0.00123	0.0166	CbGeAlD
Bromocriptine—HTR1D—female reproductive system—ovarian cancer	0.00123	0.0166	CbGeAlD
Bromocriptine—HTR2C—female reproductive system—ovarian cancer	0.00122	0.0164	CbGeAlD
Bromocriptine—ADRA2C—uterine cervix—ovarian cancer	0.0012	0.0162	CbGeAlD
Bromocriptine—ADRB1—female reproductive system—ovarian cancer	0.0012	0.0161	CbGeAlD
Bromocriptine—Dihydroergotamine—ABCB1—ovarian cancer	0.00118	0.412	CrCbGaD
Bromocriptine—ADRA2C—decidua—ovarian cancer	0.00115	0.0154	CbGeAlD
Bromocriptine—HTR2B—female reproductive system—ovarian cancer	0.00114	0.0154	CbGeAlD
Bromocriptine—HTR7—gonad—ovarian cancer	0.0011	0.0148	CbGeAlD
Bromocriptine—ADRA2C—endometrium—ovarian cancer	0.00109	0.0146	CbGeAlD
Bromocriptine—Ergonovine—ABCB1—ovarian cancer	0.00108	0.376	CrCbGaD
Bromocriptine—HTR2B—vagina—ovarian cancer	0.00104	0.0139	CbGeAlD
Bromocriptine—HTR2A—embryo—ovarian cancer	0.00101	0.0136	CbGeAlD
Bromocriptine—ADRA2C—uterus—ovarian cancer	0.001	0.0135	CbGeAlD
Bromocriptine—HTR7—female reproductive system—ovarian cancer	0.00098	0.0132	CbGeAlD
Bromocriptine—ADRA2A—uterine cervix—ovarian cancer	0.000959	0.0129	CbGeAlD
Bromocriptine—ADRA2A—decidua—ovarian cancer	0.000914	0.0123	CbGeAlD
Bromocriptine—ADRA2A—endometrium—ovarian cancer	0.000868	0.0117	CbGeAlD
Bromocriptine—HTR2A—epithelium—ovarian cancer	0.000823	0.0111	CbGeAlD
Bromocriptine—ADRA2C—female gonad—ovarian cancer	0.00082	0.011	CbGeAlD
Bromocriptine—ADRA2C—vagina—ovarian cancer	0.000815	0.011	CbGeAlD
Bromocriptine—ADRA2A—gonad—ovarian cancer	0.000805	0.0108	CbGeAlD
Bromocriptine—ADRA2A—uterus—ovarian cancer	0.0008	0.0108	CbGeAlD
Bromocriptine—HTR7—testis—ovarian cancer	0.000791	0.0106	CbGeAlD
Bromocriptine—DRD2—testis—ovarian cancer	0.000748	0.0101	CbGeAlD
Bromocriptine—ADRA2C—testis—ovarian cancer	0.000727	0.00978	CbGeAlD
Bromocriptine—ADRA2A—female reproductive system—ovarian cancer	0.000719	0.00967	CbGeAlD
Bromocriptine—ABCB1—myometrium—ovarian cancer	0.000687	0.00924	CbGeAlD
Bromocriptine—HTR2A—gonad—ovarian cancer	0.000684	0.00921	CbGeAlD
Bromocriptine—HTR2B—lymph node—ovarian cancer	0.00067	0.00901	CbGeAlD
Bromocriptine—ABCB1—embryo—ovarian cancer	0.000661	0.00889	CbGeAlD
Bromocriptine—ADRA2A—female gonad—ovarian cancer	0.000654	0.0088	CbGeAlD
Bromocriptine—ADRA2A—vagina—ovarian cancer	0.00065	0.00875	CbGeAlD
Bromocriptine—HTR2A—female reproductive system—ovarian cancer	0.000611	0.00822	CbGeAlD
Bromocriptine—Ergotamine—ABCB1—ovarian cancer	0.00061	0.212	CrCbGaD
Bromocriptine—ADRA2A—testis—ovarian cancer	0.00058	0.00781	CbGeAlD
Bromocriptine—CYP3A4—female reproductive system—ovarian cancer	0.000566	0.00761	CbGeAlD
Bromocriptine—HTR2A—vagina—ovarian cancer	0.000553	0.00744	CbGeAlD
Bromocriptine—ABCB1—epithelium—ovarian cancer	0.000539	0.00725	CbGeAlD
Bromocriptine—ABCB1—uterine cervix—ovarian cancer	0.000535	0.00719	CbGeAlD
Bromocriptine—ADRA2C—lymph node—ovarian cancer	0.000527	0.00709	CbGeAlD
Bromocriptine—ABCB1—decidua—ovarian cancer	0.000509	0.00685	CbGeAlD
Bromocriptine—HTR2A—testis—ovarian cancer	0.000493	0.00664	CbGeAlD
Bromocriptine—ABCB1—endometrium—ovarian cancer	0.000484	0.00651	CbGeAlD
Bromocriptine—Diarrhoea—Melphalan—ovarian cancer	0.000461	0.00135	CcSEcCtD
Bromocriptine—Diplopia—Epirubicin—ovarian cancer	0.00046	0.00134	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.00046	0.00134	CcSEcCtD
Bromocriptine—Nausea—Chlorambucil—ovarian cancer	0.000459	0.00134	CcSEcCtD
Bromocriptine—Vision blurred—Paclitaxel—ovarian cancer	0.000457	0.00133	CcSEcCtD
Bromocriptine—Visual impairment—Docetaxel—ovarian cancer	0.000455	0.00133	CcSEcCtD
Bromocriptine—Dizziness—Topotecan—ovarian cancer	0.000455	0.00133	CcSEcCtD
Bromocriptine—ABCB1—gonad—ovarian cancer	0.000449	0.00603	CbGeAlD
Bromocriptine—ABCB1—uterus—ovarian cancer	0.000446	0.00599	CbGeAlD
Bromocriptine—Agitation—Paclitaxel—ovarian cancer	0.000446	0.0013	CcSEcCtD
Bromocriptine—Eye disorder—Docetaxel—ovarian cancer	0.000441	0.00129	CcSEcCtD
Bromocriptine—Cardiac disorder—Docetaxel—ovarian cancer	0.000438	0.00128	CcSEcCtD
Bromocriptine—Vomiting—Topotecan—ovarian cancer	0.000437	0.00128	CcSEcCtD
Bromocriptine—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000436	0.00127	CcSEcCtD
Bromocriptine—Vertigo—Paclitaxel—ovarian cancer	0.000436	0.00127	CcSEcCtD
Bromocriptine—Syncope—Paclitaxel—ovarian cancer	0.000435	0.00127	CcSEcCtD
Bromocriptine—Lethargy—Doxorubicin—ovarian cancer	0.000435	0.00127	CcSEcCtD
Bromocriptine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000435	0.00127	CcSEcCtD
Bromocriptine—Rash—Topotecan—ovarian cancer	0.000434	0.00127	CcSEcCtD
Bromocriptine—Dermatitis—Topotecan—ovarian cancer	0.000433	0.00126	CcSEcCtD
Bromocriptine—Ataxia—Epirubicin—ovarian cancer	0.000433	0.00126	CcSEcCtD
Bromocriptine—Headache—Topotecan—ovarian cancer	0.000431	0.00126	CcSEcCtD
Bromocriptine—Angiopathy—Docetaxel—ovarian cancer	0.000428	0.00125	CcSEcCtD
Bromocriptine—Vomiting—Melphalan—ovarian cancer	0.000428	0.00125	CcSEcCtD
Bromocriptine—Loss of consciousness—Paclitaxel—ovarian cancer	0.000426	0.00124	CcSEcCtD
Bromocriptine—Diplopia—Doxorubicin—ovarian cancer	0.000426	0.00124	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000426	0.00124	CcSEcCtD
Bromocriptine—Mediastinal disorder—Docetaxel—ovarian cancer	0.000425	0.00124	CcSEcCtD
Bromocriptine—Rash—Melphalan—ovarian cancer	0.000425	0.00124	CcSEcCtD
Bromocriptine—Dermatitis—Melphalan—ovarian cancer	0.000424	0.00124	CcSEcCtD
Bromocriptine—Asthenia—Vinorelbine—ovarian cancer	0.000422	0.00123	CcSEcCtD
Bromocriptine—Arrhythmia—Docetaxel—ovarian cancer	0.000422	0.00123	CcSEcCtD
Bromocriptine—ADRA2A—lymph node—ovarian cancer	0.000421	0.00566	CbGeAlD
Bromocriptine—Orthostatic hypotension—Epirubicin—ovarian cancer	0.00042	0.00123	CcSEcCtD
Bromocriptine—Abdominal pain upper—Epirubicin—ovarian cancer	0.00042	0.00123	CcSEcCtD
Bromocriptine—Convulsion—Paclitaxel—ovarian cancer	0.00042	0.00123	CcSEcCtD
Bromocriptine—Hypertension—Paclitaxel—ovarian cancer	0.000419	0.00122	CcSEcCtD
Bromocriptine—Alopecia—Docetaxel—ovarian cancer	0.000417	0.00122	CcSEcCtD
Bromocriptine—Mental disorder—Docetaxel—ovarian cancer	0.000414	0.00121	CcSEcCtD
Bromocriptine—Nasopharyngitis—Epirubicin—ovarian cancer	0.000412	0.0012	CcSEcCtD
Bromocriptine—Anxiety—Paclitaxel—ovarian cancer	0.000411	0.0012	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00041	0.0012	CcSEcCtD
Bromocriptine—Nausea—Topotecan—ovarian cancer	0.000408	0.00119	CcSEcCtD
Bromocriptine—Dry mouth—Paclitaxel—ovarian cancer	0.000404	0.00118	CcSEcCtD
Bromocriptine—Diarrhoea—Vinorelbine—ovarian cancer	0.000403	0.00118	CcSEcCtD
Bromocriptine—Dysgeusia—Docetaxel—ovarian cancer	0.000402	0.00117	CcSEcCtD
Bromocriptine—ABCB1—female reproductive system—ovarian cancer	0.000401	0.00539	CbGeAlD
Bromocriptine—Ataxia—Doxorubicin—ovarian cancer	0.0004	0.00117	CcSEcCtD
Bromocriptine—Nausea—Melphalan—ovarian cancer	0.0004	0.00117	CcSEcCtD
Bromocriptine—Confusional state—Paclitaxel—ovarian cancer	0.000399	0.00116	CcSEcCtD
Bromocriptine—Influenza—Epirubicin—ovarian cancer	0.000398	0.00116	CcSEcCtD
Bromocriptine—Dysphagia—Epirubicin—ovarian cancer	0.000398	0.00116	CcSEcCtD
Bromocriptine—Oedema—Paclitaxel—ovarian cancer	0.000396	0.00116	CcSEcCtD
Bromocriptine—Muscle spasms—Docetaxel—ovarian cancer	0.000395	0.00115	CcSEcCtD
Bromocriptine—Infection—Paclitaxel—ovarian cancer	0.000393	0.00115	CcSEcCtD
Bromocriptine—Shock—Paclitaxel—ovarian cancer	0.000389	0.00114	CcSEcCtD
Bromocriptine—Dizziness—Vinorelbine—ovarian cancer	0.000389	0.00114	CcSEcCtD
Bromocriptine—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000389	0.00114	CcSEcCtD
Bromocriptine—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000389	0.00114	CcSEcCtD
Bromocriptine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000388	0.00113	CcSEcCtD
Bromocriptine—Tachycardia—Paclitaxel—ovarian cancer	0.000386	0.00113	CcSEcCtD
Bromocriptine—Skin disorder—Paclitaxel—ovarian cancer	0.000384	0.00112	CcSEcCtD
Bromocriptine—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000381	0.00111	CcSEcCtD
Bromocriptine—ABCB1—bone marrow—ovarian cancer	0.000378	0.00509	CbGeAlD
Bromocriptine—Anorexia—Paclitaxel—ovarian cancer	0.000377	0.0011	CcSEcCtD
Bromocriptine—Vomiting—Vinorelbine—ovarian cancer	0.000374	0.00109	CcSEcCtD
Bromocriptine—Rash—Vinorelbine—ovarian cancer	0.000371	0.00108	CcSEcCtD
Bromocriptine—Dermatitis—Vinorelbine—ovarian cancer	0.000371	0.00108	CcSEcCtD
Bromocriptine—Hypotension—Paclitaxel—ovarian cancer	0.00037	0.00108	CcSEcCtD
Bromocriptine—Headache—Vinorelbine—ovarian cancer	0.000369	0.00108	CcSEcCtD
Bromocriptine—Syncope—Docetaxel—ovarian cancer	0.000369	0.00108	CcSEcCtD
Bromocriptine—Influenza—Doxorubicin—ovarian cancer	0.000368	0.00107	CcSEcCtD
Bromocriptine—Dysphagia—Doxorubicin—ovarian cancer	0.000368	0.00107	CcSEcCtD
Bromocriptine—Pollakiuria—Epirubicin—ovarian cancer	0.000367	0.00107	CcSEcCtD
Bromocriptine—ABCB1—female gonad—ovarian cancer	0.000364	0.0049	CbGeAlD
Bromocriptine—ABCB1—vagina—ovarian cancer	0.000362	0.00487	CbGeAlD
Bromocriptine—Loss of consciousness—Docetaxel—ovarian cancer	0.000361	0.00105	CcSEcCtD
Bromocriptine—Insomnia—Paclitaxel—ovarian cancer	0.000358	0.00104	CcSEcCtD
Bromocriptine—Convulsion—Docetaxel—ovarian cancer	0.000356	0.00104	CcSEcCtD
Bromocriptine—Paraesthesia—Paclitaxel—ovarian cancer	0.000355	0.00104	CcSEcCtD
Bromocriptine—Hypertension—Docetaxel—ovarian cancer	0.000355	0.00104	CcSEcCtD
Bromocriptine—Drowsiness—Epirubicin—ovarian cancer	0.000355	0.00104	CcSEcCtD
Bromocriptine—Dyspnoea—Paclitaxel—ovarian cancer	0.000353	0.00103	CcSEcCtD
Bromocriptine—Somnolence—Paclitaxel—ovarian cancer	0.000352	0.00103	CcSEcCtD
Bromocriptine—Nausea—Vinorelbine—ovarian cancer	0.000349	0.00102	CcSEcCtD
Bromocriptine—Dyspepsia—Paclitaxel—ovarian cancer	0.000348	0.00102	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000347	0.00101	CcSEcCtD
Bromocriptine—Decreased appetite—Paclitaxel—ovarian cancer	0.000344	0.001	CcSEcCtD
Bromocriptine—Dry mouth—Docetaxel—ovarian cancer	0.000342	0.000999	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000342	0.000997	CcSEcCtD
Bromocriptine—Fatigue—Paclitaxel—ovarian cancer	0.000341	0.000996	CcSEcCtD
Bromocriptine—Pollakiuria—Doxorubicin—ovarian cancer	0.00034	0.000993	CcSEcCtD
Bromocriptine—Constipation—Paclitaxel—ovarian cancer	0.000338	0.000988	CcSEcCtD
Bromocriptine—Confusional state—Docetaxel—ovarian cancer	0.000338	0.000987	CcSEcCtD
Bromocriptine—Oedema—Docetaxel—ovarian cancer	0.000335	0.000979	CcSEcCtD
Bromocriptine—Infection—Docetaxel—ovarian cancer	0.000333	0.000973	CcSEcCtD
Bromocriptine—Sinusitis—Epirubicin—ovarian cancer	0.000333	0.000972	CcSEcCtD
Bromocriptine—Shock—Docetaxel—ovarian cancer	0.00033	0.000963	CcSEcCtD
Bromocriptine—Nervous system disorder—Docetaxel—ovarian cancer	0.000329	0.00096	CcSEcCtD
Bromocriptine—Drowsiness—Doxorubicin—ovarian cancer	0.000328	0.000958	CcSEcCtD
Bromocriptine—Tachycardia—Docetaxel—ovarian cancer	0.000327	0.000956	CcSEcCtD
Bromocriptine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000326	0.000952	CcSEcCtD
Bromocriptine—Skin disorder—Docetaxel—ovarian cancer	0.000326	0.000951	CcSEcCtD
Bromocriptine—Bradycardia—Epirubicin—ovarian cancer	0.000324	0.000946	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000324	0.000945	CcSEcCtD
Bromocriptine—ABCB1—testis—ovarian cancer	0.000323	0.00435	CbGeAlD
Bromocriptine—Anorexia—Docetaxel—ovarian cancer	0.00032	0.000933	CcSEcCtD
Bromocriptine—Rhinitis—Epirubicin—ovarian cancer	0.000319	0.000932	CcSEcCtD
Bromocriptine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000317	0.000925	CcSEcCtD
Bromocriptine—Urticaria—Paclitaxel—ovarian cancer	0.000314	0.000918	CcSEcCtD
Bromocriptine—Oedema peripheral—Epirubicin—ovarian cancer	0.000314	0.000916	CcSEcCtD
Bromocriptine—Hypotension—Docetaxel—ovarian cancer	0.000313	0.000915	CcSEcCtD
Bromocriptine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000313	0.000914	CcSEcCtD
Bromocriptine—Body temperature increased—Paclitaxel—ovarian cancer	0.000313	0.000913	CcSEcCtD
Bromocriptine—Abdominal pain—Paclitaxel—ovarian cancer	0.000313	0.000913	CcSEcCtD
Bromocriptine—Sinusitis—Doxorubicin—ovarian cancer	0.000308	0.000899	CcSEcCtD
Bromocriptine—Visual impairment—Epirubicin—ovarian cancer	0.000307	0.000896	CcSEcCtD
Bromocriptine—Insomnia—Docetaxel—ovarian cancer	0.000303	0.000886	CcSEcCtD
Bromocriptine—Paraesthesia—Docetaxel—ovarian cancer	0.000301	0.000879	CcSEcCtD
Bromocriptine—Bradycardia—Doxorubicin—ovarian cancer	0.0003	0.000876	CcSEcCtD
Bromocriptine—Dyspnoea—Docetaxel—ovarian cancer	0.000299	0.000873	CcSEcCtD
Bromocriptine—Somnolence—Docetaxel—ovarian cancer	0.000298	0.000871	CcSEcCtD
Bromocriptine—Eye disorder—Epirubicin—ovarian cancer	0.000298	0.000869	CcSEcCtD
Bromocriptine—Tinnitus—Epirubicin—ovarian cancer	0.000297	0.000867	CcSEcCtD
Bromocriptine—Cardiac disorder—Epirubicin—ovarian cancer	0.000296	0.000863	CcSEcCtD
Bromocriptine—Rhinitis—Doxorubicin—ovarian cancer	0.000295	0.000862	CcSEcCtD
Bromocriptine—Dyspepsia—Docetaxel—ovarian cancer	0.000295	0.000862	CcSEcCtD
Bromocriptine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000293	0.000856	CcSEcCtD
Bromocriptine—Decreased appetite—Docetaxel—ovarian cancer	0.000292	0.000851	CcSEcCtD
Bromocriptine—Oedema peripheral—Doxorubicin—ovarian cancer	0.00029	0.000847	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00029	0.000845	CcSEcCtD
Bromocriptine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00029	0.000845	CcSEcCtD
Bromocriptine—Fatigue—Docetaxel—ovarian cancer	0.000289	0.000844	CcSEcCtD
Bromocriptine—Angiopathy—Epirubicin—ovarian cancer	0.000289	0.000843	CcSEcCtD
Bromocriptine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000287	0.000838	CcSEcCtD
Bromocriptine—Constipation—Docetaxel—ovarian cancer	0.000287	0.000837	CcSEcCtD
Bromocriptine—Arrhythmia—Epirubicin—ovarian cancer	0.000284	0.000831	CcSEcCtD
Bromocriptine—Visual impairment—Doxorubicin—ovarian cancer	0.000284	0.000829	CcSEcCtD
Bromocriptine—Asthenia—Paclitaxel—ovarian cancer	0.000284	0.000829	CcSEcCtD
Bromocriptine—Alopecia—Epirubicin—ovarian cancer	0.000281	0.000822	CcSEcCtD
Bromocriptine—Mental disorder—Epirubicin—ovarian cancer	0.000279	0.000814	CcSEcCtD
Bromocriptine—Feeling abnormal—Docetaxel—ovarian cancer	0.000276	0.000807	CcSEcCtD
Bromocriptine—Eye disorder—Doxorubicin—ovarian cancer	0.000275	0.000804	CcSEcCtD
Bromocriptine—Tinnitus—Doxorubicin—ovarian cancer	0.000275	0.000802	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000274	0.000801	CcSEcCtD
Bromocriptine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000273	0.000798	CcSEcCtD
Bromocriptine—Tension—Epirubicin—ovarian cancer	0.000272	0.000794	CcSEcCtD
Bromocriptine—Dysgeusia—Epirubicin—ovarian cancer	0.000271	0.000793	CcSEcCtD
Bromocriptine—Diarrhoea—Paclitaxel—ovarian cancer	0.000271	0.00079	CcSEcCtD
Bromocriptine—Nervousness—Epirubicin—ovarian cancer	0.000269	0.000786	CcSEcCtD
Bromocriptine—Angiopathy—Doxorubicin—ovarian cancer	0.000267	0.00078	CcSEcCtD
Bromocriptine—Muscle spasms—Epirubicin—ovarian cancer	0.000266	0.000778	CcSEcCtD
Bromocriptine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000266	0.000775	CcSEcCtD
Bromocriptine—Body temperature increased—Docetaxel—ovarian cancer	0.000265	0.000774	CcSEcCtD
Bromocriptine—Abdominal pain—Docetaxel—ovarian cancer	0.000265	0.000774	CcSEcCtD
Bromocriptine—Arrhythmia—Doxorubicin—ovarian cancer	0.000263	0.000768	CcSEcCtD
Bromocriptine—Dizziness—Paclitaxel—ovarian cancer	0.000262	0.000764	CcSEcCtD
Bromocriptine—Vision blurred—Epirubicin—ovarian cancer	0.000261	0.000763	CcSEcCtD
Bromocriptine—Alopecia—Doxorubicin—ovarian cancer	0.00026	0.00076	CcSEcCtD
Bromocriptine—Mental disorder—Doxorubicin—ovarian cancer	0.000258	0.000754	CcSEcCtD
Bromocriptine—Agitation—Epirubicin—ovarian cancer	0.000255	0.000744	CcSEcCtD
Bromocriptine—Tension—Doxorubicin—ovarian cancer	0.000252	0.000735	CcSEcCtD
Bromocriptine—Vomiting—Paclitaxel—ovarian cancer	0.000252	0.000735	CcSEcCtD
Bromocriptine—Dysgeusia—Doxorubicin—ovarian cancer	0.000251	0.000733	CcSEcCtD
Bromocriptine—Rash—Paclitaxel—ovarian cancer	0.000249	0.000728	CcSEcCtD
Bromocriptine—Dermatitis—Paclitaxel—ovarian cancer	0.000249	0.000728	CcSEcCtD
Bromocriptine—Nervousness—Doxorubicin—ovarian cancer	0.000249	0.000727	CcSEcCtD
Bromocriptine—Vertigo—Epirubicin—ovarian cancer	0.000249	0.000727	CcSEcCtD
Bromocriptine—Syncope—Epirubicin—ovarian cancer	0.000249	0.000726	CcSEcCtD
Bromocriptine—Headache—Paclitaxel—ovarian cancer	0.000248	0.000724	CcSEcCtD
Bromocriptine—Muscle spasms—Doxorubicin—ovarian cancer	0.000247	0.00072	CcSEcCtD
Bromocriptine—Loss of consciousness—Epirubicin—ovarian cancer	0.000244	0.000711	CcSEcCtD
Bromocriptine—Vision blurred—Doxorubicin—ovarian cancer	0.000242	0.000706	CcSEcCtD
Bromocriptine—Asthenia—Docetaxel—ovarian cancer	0.000241	0.000703	CcSEcCtD
Bromocriptine—Convulsion—Epirubicin—ovarian cancer	0.00024	0.000701	CcSEcCtD
Bromocriptine—Hypertension—Epirubicin—ovarian cancer	0.000239	0.000699	CcSEcCtD
Bromocriptine—Agitation—Doxorubicin—ovarian cancer	0.000236	0.000688	CcSEcCtD
Bromocriptine—Anxiety—Epirubicin—ovarian cancer	0.000235	0.000687	CcSEcCtD
Bromocriptine—Nausea—Paclitaxel—ovarian cancer	0.000235	0.000686	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000234	0.000684	CcSEcCtD
Bromocriptine—ABCB1—lymph node—ovarian cancer	0.000234	0.00315	CbGeAlD
Bromocriptine—Dry mouth—Epirubicin—ovarian cancer	0.000231	0.000674	CcSEcCtD
Bromocriptine—Vertigo—Doxorubicin—ovarian cancer	0.00023	0.000673	CcSEcCtD
Bromocriptine—Syncope—Doxorubicin—ovarian cancer	0.00023	0.000672	CcSEcCtD
Bromocriptine—Diarrhoea—Docetaxel—ovarian cancer	0.000229	0.00067	CcSEcCtD
Bromocriptine—Confusional state—Epirubicin—ovarian cancer	0.000228	0.000666	CcSEcCtD
Bromocriptine—Oedema—Epirubicin—ovarian cancer	0.000226	0.000661	CcSEcCtD
Bromocriptine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000225	0.000658	CcSEcCtD
Bromocriptine—Infection—Epirubicin—ovarian cancer	0.000225	0.000656	CcSEcCtD
Bromocriptine—Shock—Epirubicin—ovarian cancer	0.000223	0.00065	CcSEcCtD
Bromocriptine—Convulsion—Doxorubicin—ovarian cancer	0.000222	0.000649	CcSEcCtD
Bromocriptine—Nervous system disorder—Epirubicin—ovarian cancer	0.000222	0.000648	CcSEcCtD
Bromocriptine—Dizziness—Docetaxel—ovarian cancer	0.000222	0.000648	CcSEcCtD
Bromocriptine—Hypertension—Doxorubicin—ovarian cancer	0.000221	0.000647	CcSEcCtD
Bromocriptine—Tachycardia—Epirubicin—ovarian cancer	0.000221	0.000645	CcSEcCtD
Bromocriptine—Skin disorder—Epirubicin—ovarian cancer	0.00022	0.000642	CcSEcCtD
Bromocriptine—Anxiety—Doxorubicin—ovarian cancer	0.000218	0.000635	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000217	0.000633	CcSEcCtD
Bromocriptine—Anorexia—Epirubicin—ovarian cancer	0.000216	0.00063	CcSEcCtD
Bromocriptine—Dry mouth—Doxorubicin—ovarian cancer	0.000214	0.000623	CcSEcCtD
Bromocriptine—Vomiting—Docetaxel—ovarian cancer	0.000213	0.000623	CcSEcCtD
Bromocriptine—Rash—Docetaxel—ovarian cancer	0.000211	0.000617	CcSEcCtD
Bromocriptine—Hypotension—Epirubicin—ovarian cancer	0.000211	0.000617	CcSEcCtD
Bromocriptine—Dermatitis—Docetaxel—ovarian cancer	0.000211	0.000617	CcSEcCtD
Bromocriptine—Confusional state—Doxorubicin—ovarian cancer	0.000211	0.000616	CcSEcCtD
Bromocriptine—Headache—Docetaxel—ovarian cancer	0.00021	0.000613	CcSEcCtD
Bromocriptine—Oedema—Doxorubicin—ovarian cancer	0.000209	0.000611	CcSEcCtD
Bromocriptine—Infection—Doxorubicin—ovarian cancer	0.000208	0.000607	CcSEcCtD
Bromocriptine—Shock—Doxorubicin—ovarian cancer	0.000206	0.000601	CcSEcCtD
Bromocriptine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000205	0.000599	CcSEcCtD
Bromocriptine—Insomnia—Epirubicin—ovarian cancer	0.000205	0.000597	CcSEcCtD
Bromocriptine—Tachycardia—Doxorubicin—ovarian cancer	0.000204	0.000596	CcSEcCtD
Bromocriptine—Skin disorder—Doxorubicin—ovarian cancer	0.000203	0.000594	CcSEcCtD
Bromocriptine—Paraesthesia—Epirubicin—ovarian cancer	0.000203	0.000593	CcSEcCtD
Bromocriptine—Dyspnoea—Epirubicin—ovarian cancer	0.000202	0.000589	CcSEcCtD
Bromocriptine—Somnolence—Epirubicin—ovarian cancer	0.000201	0.000587	CcSEcCtD
Bromocriptine—Anorexia—Doxorubicin—ovarian cancer	0.0002	0.000583	CcSEcCtD
Bromocriptine—Nausea—Docetaxel—ovarian cancer	0.000199	0.000582	CcSEcCtD
Bromocriptine—Dyspepsia—Epirubicin—ovarian cancer	0.000199	0.000581	CcSEcCtD
Bromocriptine—Decreased appetite—Epirubicin—ovarian cancer	0.000197	0.000574	CcSEcCtD
Bromocriptine—Hypotension—Doxorubicin—ovarian cancer	0.000196	0.000571	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000195	0.00057	CcSEcCtD
Bromocriptine—Fatigue—Epirubicin—ovarian cancer	0.000195	0.000569	CcSEcCtD
Bromocriptine—Constipation—Epirubicin—ovarian cancer	0.000193	0.000565	CcSEcCtD
Bromocriptine—Insomnia—Doxorubicin—ovarian cancer	0.000189	0.000553	CcSEcCtD
Bromocriptine—Paraesthesia—Doxorubicin—ovarian cancer	0.000188	0.000549	CcSEcCtD
Bromocriptine—Dyspnoea—Doxorubicin—ovarian cancer	0.000187	0.000545	CcSEcCtD
Bromocriptine—Feeling abnormal—Epirubicin—ovarian cancer	0.000186	0.000544	CcSEcCtD
Bromocriptine—Somnolence—Doxorubicin—ovarian cancer	0.000186	0.000543	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000185	0.00054	CcSEcCtD
Bromocriptine—Dyspepsia—Doxorubicin—ovarian cancer	0.000184	0.000538	CcSEcCtD
Bromocriptine—Decreased appetite—Doxorubicin—ovarian cancer	0.000182	0.000531	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000181	0.000528	CcSEcCtD
Bromocriptine—Fatigue—Doxorubicin—ovarian cancer	0.00018	0.000527	CcSEcCtD
Bromocriptine—Urticaria—Epirubicin—ovarian cancer	0.00018	0.000525	CcSEcCtD
Bromocriptine—Constipation—Doxorubicin—ovarian cancer	0.000179	0.000523	CcSEcCtD
Bromocriptine—Abdominal pain—Epirubicin—ovarian cancer	0.000179	0.000522	CcSEcCtD
Bromocriptine—Body temperature increased—Epirubicin—ovarian cancer	0.000179	0.000522	CcSEcCtD
Bromocriptine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000172	0.000504	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000171	0.0005	CcSEcCtD
Bromocriptine—Urticaria—Doxorubicin—ovarian cancer	0.000166	0.000486	CcSEcCtD
Bromocriptine—Abdominal pain—Doxorubicin—ovarian cancer	0.000165	0.000483	CcSEcCtD
Bromocriptine—Body temperature increased—Doxorubicin—ovarian cancer	0.000165	0.000483	CcSEcCtD
Bromocriptine—Asthenia—Epirubicin—ovarian cancer	0.000162	0.000474	CcSEcCtD
Bromocriptine—Diarrhoea—Epirubicin—ovarian cancer	0.000155	0.000452	CcSEcCtD
Bromocriptine—Asthenia—Doxorubicin—ovarian cancer	0.00015	0.000438	CcSEcCtD
Bromocriptine—Dizziness—Epirubicin—ovarian cancer	0.00015	0.000437	CcSEcCtD
Bromocriptine—Vomiting—Epirubicin—ovarian cancer	0.000144	0.00042	CcSEcCtD
Bromocriptine—Diarrhoea—Doxorubicin—ovarian cancer	0.000143	0.000418	CcSEcCtD
Bromocriptine—Rash—Epirubicin—ovarian cancer	0.000143	0.000416	CcSEcCtD
Bromocriptine—Dermatitis—Epirubicin—ovarian cancer	0.000143	0.000416	CcSEcCtD
Bromocriptine—Headache—Epirubicin—ovarian cancer	0.000142	0.000414	CcSEcCtD
Bromocriptine—Dizziness—Doxorubicin—ovarian cancer	0.000138	0.000404	CcSEcCtD
Bromocriptine—Nausea—Epirubicin—ovarian cancer	0.000134	0.000392	CcSEcCtD
Bromocriptine—Vomiting—Doxorubicin—ovarian cancer	0.000133	0.000389	CcSEcCtD
Bromocriptine—Rash—Doxorubicin—ovarian cancer	0.000132	0.000385	CcSEcCtD
Bromocriptine—Dermatitis—Doxorubicin—ovarian cancer	0.000132	0.000385	CcSEcCtD
Bromocriptine—Headache—Doxorubicin—ovarian cancer	0.000131	0.000383	CcSEcCtD
Bromocriptine—Nausea—Doxorubicin—ovarian cancer	0.000124	0.000363	CcSEcCtD
Bromocriptine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	4.31e-06	0.000113	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	4.3e-06	0.000113	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—STAT3—ovarian cancer	4.29e-06	0.000113	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	4.29e-06	0.000113	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—CASP3—ovarian cancer	4.29e-06	0.000113	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IL2—ovarian cancer	4.28e-06	0.000112	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	4.28e-06	0.000112	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—MAPK1—ovarian cancer	4.28e-06	0.000112	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—NRAS—ovarian cancer	4.28e-06	0.000112	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	4.28e-06	0.000112	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—EGFR—ovarian cancer	4.28e-06	0.000112	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	4.27e-06	0.000112	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—IL6—ovarian cancer	4.26e-06	0.000112	CbGpPWpGaD
Bromocriptine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	4.26e-06	0.000112	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	4.25e-06	0.000112	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	4.25e-06	0.000112	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	4.24e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—TP53—ovarian cancer	4.23e-06	0.000111	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	4.23e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—TP53—ovarian cancer	4.23e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	4.22e-06	0.000111	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	4.22e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IL2—ovarian cancer	4.22e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—TP53—ovarian cancer	4.2e-06	0.00011	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	4.2e-06	0.00011	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	4.18e-06	0.00011	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—CCND1—ovarian cancer	4.18e-06	0.00011	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	4.18e-06	0.00011	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	4.18e-06	0.00011	CbGpPWpGaD
Bromocriptine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	4.17e-06	0.000109	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.15e-06	0.000109	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	4.15e-06	0.000109	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	4.14e-06	0.000108	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	4.13e-06	0.000108	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	4.13e-06	0.000108	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	4.13e-06	0.000108	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—TP53—ovarian cancer	4.11e-06	0.000108	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	4.11e-06	0.000108	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	4.11e-06	0.000108	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—STAT3—ovarian cancer	4.11e-06	0.000108	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	4.1e-06	0.000108	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—KRAS—ovarian cancer	4.1e-06	0.000108	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—NRAS—ovarian cancer	4.1e-06	0.000107	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	4.09e-06	0.000107	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	4.08e-06	0.000107	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	4.07e-06	0.000107	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	4.06e-06	0.000107	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—MMP9—ovarian cancer	4.06e-06	0.000106	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—HRAS—ovarian cancer	4.05e-06	0.000106	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—TP53—ovarian cancer	4.05e-06	0.000106	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	4.05e-06	0.000106	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—KRAS—ovarian cancer	4.05e-06	0.000106	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—HRAS—ovarian cancer	4.04e-06	0.000106	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—PTEN—ovarian cancer	4.03e-06	0.000106	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	4.02e-06	0.000106	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—HRAS—ovarian cancer	4.02e-06	0.000105	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	4.01e-06	0.000105	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	4.01e-06	0.000105	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	3.99e-06	0.000105	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	3.99e-06	0.000105	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—MYC—ovarian cancer	3.99e-06	0.000105	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	3.99e-06	0.000105	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	3.99e-06	0.000105	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	3.97e-06	0.000104	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	3.97e-06	0.000104	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	3.96e-06	0.000104	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.96e-06	0.000104	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	3.95e-06	0.000104	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CAV1—ovarian cancer	3.95e-06	0.000104	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	3.95e-06	0.000104	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—HRAS—ovarian cancer	3.93e-06	0.000103	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	3.93e-06	0.000103	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	3.92e-06	0.000103	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	3.92e-06	0.000103	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	3.91e-06	0.000103	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	3.91e-06	0.000102	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	3.9e-06	0.000102	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	3.9e-06	0.000102	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	3.9e-06	0.000102	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	3.9e-06	0.000102	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	3.88e-06	0.000102	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	3.88e-06	0.000102	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—IL6—ovarian cancer	3.88e-06	0.000102	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—HRAS—ovarian cancer	3.87e-06	0.000102	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—IL6—ovarian cancer	3.87e-06	0.000102	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	3.87e-06	0.000101	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	3.87e-06	0.000101	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	3.87e-06	0.000101	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—TP53—ovarian cancer	3.86e-06	0.000101	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.85e-06	0.000101	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—IL6—ovarian cancer	3.85e-06	0.000101	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	3.84e-06	0.000101	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	3.84e-06	0.000101	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	3.82e-06	0.0001	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—MYC—ovarian cancer	3.82e-06	0.0001	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	3.8e-06	9.96e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—MYC—ovarian cancer	3.8e-06	9.96e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	3.79e-06	9.94e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—TYMS—ovarian cancer	3.78e-06	9.92e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.77e-06	9.9e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	3.77e-06	9.88e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—IL6—ovarian cancer	3.77e-06	9.87e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	3.75e-06	9.83e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	3.74e-06	9.81e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	3.74e-06	9.8e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	3.73e-06	9.79e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	3.73e-06	9.79e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	3.72e-06	9.75e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	3.72e-06	9.75e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	3.71e-06	9.74e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	3.71e-06	9.74e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—IL6—ovarian cancer	3.71e-06	9.72e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	3.7e-06	9.71e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—HRAS—ovarian cancer	3.7e-06	9.69e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	3.69e-06	9.68e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	3.69e-06	9.67e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	3.65e-06	9.58e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—TP53—ovarian cancer	3.64e-06	9.56e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	3.64e-06	9.55e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	3.63e-06	9.53e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	3.63e-06	9.52e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	3.61e-06	9.47e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	3.61e-06	9.47e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	3.61e-06	9.46e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—STAT3—ovarian cancer	3.61e-06	9.46e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	3.6e-06	9.44e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—NRAS—ovarian cancer	3.6e-06	9.43e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—TP53—ovarian cancer	3.6e-06	9.43e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—TP53—ovarian cancer	3.6e-06	9.43e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	3.58e-06	9.4e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—AKT1—ovarian cancer	3.58e-06	9.37e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—AKT1—ovarian cancer	3.57e-06	9.36e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	3.56e-06	9.32e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	3.55e-06	9.32e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—AKT1—ovarian cancer	3.55e-06	9.3e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	3.55e-06	9.3e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	3.54e-06	9.28e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—IL6—ovarian cancer	3.54e-06	9.28e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	3.53e-06	9.25e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	3.52e-06	9.23e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	3.51e-06	9.2e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	3.51e-06	9.2e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—HRAS—ovarian cancer	3.49e-06	9.14e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	3.47e-06	9.11e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—AKT1—ovarian cancer	3.47e-06	9.11e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	3.47e-06	9.09e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.45e-06	9.06e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	3.44e-06	9.03e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	3.44e-06	9.02e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—HRAS—ovarian cancer	3.44e-06	9.02e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—AKT1—ovarian cancer	3.42e-06	8.96e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	3.41e-06	8.95e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	3.39e-06	8.89e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	3.39e-06	8.88e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	3.36e-06	8.81e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	3.36e-06	8.8e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—MYC—ovarian cancer	3.35e-06	8.79e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—IL6—ovarian cancer	3.34e-06	8.75e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	3.32e-06	8.7e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—MYC—ovarian cancer	3.3e-06	8.64e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—IL6—ovarian cancer	3.29e-06	8.63e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—IL6—ovarian cancer	3.29e-06	8.63e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	3.28e-06	8.6e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—EGFR—ovarian cancer	3.28e-06	8.59e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—TP53—ovarian cancer	3.28e-06	8.59e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—AKT1—ovarian cancer	3.26e-06	8.56e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	3.26e-06	8.55e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	3.25e-06	8.51e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	3.24e-06	8.49e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	3.23e-06	8.46e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	3.23e-06	8.46e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	3.23e-06	8.46e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	3.22e-06	8.46e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	3.22e-06	8.45e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	3.22e-06	8.44e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.16e-06	8.3e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	3.16e-06	8.28e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	3.16e-06	8.28e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	3.13e-06	8.22e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—TP53—ovarian cancer	3.13e-06	8.22e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	3.13e-06	8.22e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—TP53—ovarian cancer	3.12e-06	8.18e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	3.1e-06	8.14e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—KRAS—ovarian cancer	3.1e-06	8.12e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	3.09e-06	8.09e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	3.08e-06	8.09e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—AKT1—ovarian cancer	3.08e-06	8.07e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—AKT1—ovarian cancer	3.06e-06	8.03e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CAV1—ovarian cancer	3.05e-06	8e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	3.05e-06	7.99e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	3.04e-06	7.98e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	3.04e-06	7.96e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—AKT1—ovarian cancer	3.04e-06	7.96e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	3.03e-06	7.95e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	3e-06	7.86e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—IL6—ovarian cancer	3e-06	7.86e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	3e-06	7.86e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PTEN—ovarian cancer	2.98e-06	7.83e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	2.98e-06	7.83e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	2.98e-06	7.82e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	2.98e-06	7.82e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	2.97e-06	7.79e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	2.93e-06	7.69e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	2.93e-06	7.69e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	2.9e-06	7.6e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—IL6—ovarian cancer	2.87e-06	7.52e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	2.85e-06	7.48e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—IL6—ovarian cancer	2.85e-06	7.48e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	2.84e-06	7.46e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	2.8e-06	7.34e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.78e-06	7.28e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	2.78e-06	7.28e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	2.77e-06	7.27e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	2.77e-06	7.26e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.76e-06	7.23e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—TP53—ovarian cancer	2.75e-06	7.22e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	2.74e-06	7.19e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	2.74e-06	7.19e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	2.73e-06	7.16e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—TP53—ovarian cancer	2.71e-06	7.1e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	2.65e-06	6.95e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	2.65e-06	6.94e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	2.63e-06	6.9e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—HRAS—ovarian cancer	2.63e-06	6.9e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	2.59e-06	6.79e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	2.56e-06	6.71e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	2.55e-06	6.68e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	2.54e-06	6.65e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	2.52e-06	6.61e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IL6—ovarian cancer	2.52e-06	6.6e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—AKT1—ovarian cancer	2.49e-06	6.52e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IL6—ovarian cancer	2.48e-06	6.5e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	2.46e-06	6.46e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.44e-06	6.4e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	2.43e-06	6.36e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PTEN—ovarian cancer	2.38e-06	6.25e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	2.36e-06	6.18e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.32e-06	6.09e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.29e-06	6e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	2.25e-06	5.91e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	2.24e-06	5.87e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.13e-06	5.58e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.11e-06	5.52e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.08e-06	5.45e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PTEN—ovarian cancer	1.84e-06	4.82e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—AKT1—ovarian cancer	1.72e-06	4.51e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.68e-06	4.41e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.37e-06	3.6e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.3e-06	3.4e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—AKT1—ovarian cancer	1.06e-06	2.78e-05	CbGpPWpGaD
